The NHLBI Science Moving towArds Research Translation and Therapy (SMARTT) program has been extended for a 3-year period and is planning to resume operations in February, 2016.
The mission of SMARTT is to accelerate translation of research from demonstration of efficacy in vivo to submission of an investigational new drug application (IND) to the FDA. To accomplish this, SMARTT has engaged highly qualified contractors to provide regulatory affairs support, manufacturing, and pharmacology/toxicology services to qualified projects.
Investigators who may be considering submission of an application for SMARTT services are advised that new requests will be accepted only until February 15, 2016. Requests received after that date will not be evaluated until a future application review cycle, most likely in the 3rd quarter of 2016.
Please visit the SMARTT website and select the Critical Information and Application Guidance link to learn more about the program. Select the "Submit SMARTT Application" link on the home page to initiate a new request for services.
For more information, please contact Ms. Sudie Rowshan, SMARTT Coordinating Center Project Director.